BioNTech (BNTX) closes CureVac N.V. exchange offer to bolster mRNA position

Rhea-AI Filing Summary

BioNTech SE reports that it has completed its exchange offer for all outstanding shares of CureVac N.V., following the expiration of the subsequent offering period. This means CureVac is now being acquired by BioNTech through a share-exchange structure rather than a cash-only deal. The company states that this step closes the acquisition process and is intended to strengthen BioNTech’s position in the mRNA field. The press release describing the transaction is included as an exhibit and this report is incorporated by reference into BioNTech’s existing Form F-4 registration statement.

Insights

Biopharma M&A and strategy analyst

BioNTech closes its CureVac share-exchange acquisition, consolidating mRNA assets.

BioNTech discloses that it has completed its exchange offer for all outstanding shares of CureVac N.V., with the subsequent offering period now expired. This indicates that the transaction has moved from offer stage to closing, meaning CureVac’s equity is effectively being folded into BioNTech via an equity-based structure.

The exhibit title notes that the deal is expected to strengthen BioNTech’s “unique position in the mRNA field,” highlighting an intent to consolidate intellectual property, technology, and development capabilities around mRNA. While the excerpt does not quantify the transaction size or expected synergies, it frames the acquisition as strategically important for BioNTech’s platform.

Because this report is incorporated by reference into an existing Form F-4 registration statement, it also serves a technical role in documenting that the exchange offer is complete. Subsequent disclosures in future filings may provide more detail on integration progress, pipeline implications, and financial effects of the CureVac acquisition.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF DECEMBER 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE

(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On December 18, 2025, BioNTech SE (the “Company”) issued a press release announcing the expiration of the subsequent offering period and the completion of its exchange offer for all outstanding shares of CureVac N.V. A copy of the press release is attached hereto as Exhibit 99.1.

This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company’s registration statement on Form F-4 (File No. 333-289468) and to be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE
By:		/s/ Prof. Dr. Ugur Sahin				By:		/s/ Dr. Sierk Poetting
		Name: Prof. Dr. Ugur Sahin						Name: Dr. Sierk Poetting
		Title: Chief Executive Officer						Title: Chief Operating Officer

Date: December 18, 2025

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

FAQ

What did BioNTech SE (BNTX) announce in this Form 6-K?

BioNTech SE announced that the subsequent offering period has expired and it has completed its exchange offer for all outstanding shares of CureVac N.V., effectively closing the acquisition.

How is the CureVac N.V. acquisition structured for BioNTech SE (BNTX)?

The transaction is described as an exchange offer for all outstanding shares of CureVac N.V., indicating BioNTech is acquiring CureVac by offering its own securities in exchange for CureVac shares.

What is the strategic goal of BioNTech’s acquisition of CureVac N.V.?

According to the exhibit description, BioNTech is closing the CureVac acquisition to strengthen its unique position in the mRNA field, underscoring the deal’s strategic focus on mRNA technologies.

How does this Form 6-K relate to BioNTech SE’s Form F-4 registration statement?

The report states that it is filed and incorporated by reference into BioNTech’s existing Form F-4 registration statement and will form part of that registration from the filing date unless later documents supersede it.

Where can investors find more details about BioNTech’s CureVac acquisition?

More details are contained in the attached press release, filed as Exhibit 99.1 titled “BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field.”

Who signed the BioNTech SE Form 6-K related to the CureVac acquisition?

The report is signed on behalf of BioNTech SE by Prof. Dr. Ugur Sahin, Chief Executive Officer, and Dr. Sierk Poetting, Chief Operating Officer.